Results 21 to 30 of about 1,521,289 (195)

Frequency of HER-2 over Expression in the Patients with Breast Cancer after Mastectomy

Majallah-i Dānishgāh-i ’Ulūm-i Pizishkī-i Shahīd Ṣadūqī Yazd, 2013
Introduction: HER-2 is a protein receptor of growth. Approximately 25% of breast cancers have overexpress HER-2. This study was designed to determine frequency of HER-2 overexpression in patients with breast cancer.
S kargar, B alavi farzane
doaj  

Early Body Mass Index z‐Score Change and Resolution of Severe Malnutrition in Children With Sickle Cell Anemia in a Low‐Income Setting: A Prospective Single‐Arm Extension Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Children with sickle cell anemia (SCA) in low‐income settings are at risk of severe malnutrition, but optimal nutritional management has not been established. We evaluated an intensified ready‐to‐use therapeutic food (RUTF) regimen in children with persistent severe malnutrition after initial treatment and assessed whether early ...
Safiya Gambo, Shehu Umar Abdullahi, Hassan Adam Murtala, Halima Kabir, Khadija A. Shamsu, Sari A. Acra, Virginia A. Stallings, Mark Rodeghier, Michael R. DeBaun, Lauren J. Klein   +9 more
wiley   +1 more source

Evaluation of Treatment Outcomes of HER-2-Positive Breast Cancer Patients from Provincial General Hospital Dr. M. Djamil Padang

Indonesian Journal of Cancer
Background: Human Epidermal Receptor-2 (HER-2) is a member of the human epidermal growth factor receptor family that can be overexpressed or amplified in 15—20% of breast cancer cases.
Rizqy Nurfathonah Putri, Wirsma Arif Harahap, Aswiyanti Asri   +2 more
doaj   +1 more source

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab

Frontiers in Oncology, 2022
ObjectiveTo explore the correlation between HER-2 status and pathological complete response (pCR) in HER-2-positive breast cancer after dual anti-HER-2 neoadjuvant therapy with trastuzumab and pertuzumab.MethodsA total of 57 HER-2-positive breast cancer ...
Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li   +10 more
doaj   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Comparative Drug Response Profiling in Neuroblastoma Cell Lines and Patient‐Derived Tumor Organoids

Pediatric Blood &Cancer, EarlyView.
ABSTRACT High‐risk neuroblastoma remains a leading cause of pediatric cancer mortality, and improved preclinical models are needed to guide therapeutic developments. We screened seven high‐risk neuroblastoma cell lines and three patient‐derived tumor organoids with 528 compounds alongside bone marrow controls, and compared them with external datasets ...
Krzysztof Wierbiłowicz, Se Whee Sammy Park, Aironas Los, Ernest Liu, Nona Struyf, Tom Erkers, Sören Lehmann, Jan J. Molenaar, Jakob Stenman, Olli Kallioniemi, Päivi Östling, Brinton Seashore‐Ludlow, Kasper Karlsson   +12 more
wiley   +1 more source

Guidelines for the use of tumor markers in breast cancer [PDF]

Journal of Medical Biochemistry, 2007
The best-validated markers in breast cancer are all tissue based and include estrogen receptors (ER), progesteron receptors (PR), HER-2, urokinase plasminogen activator (uPA) and plasminogen activator inhibitor 1 (PAI-1). Assay of ER, PR and HER-2 is now
Ignjatović Svetlana
doaj  

A murine model for virotherapy of malignant brain tumors

Journal of Biological Research, 2011
Glioblastomas (GBMs) are very aggressive and almost incurable brain tumors. The development of new therapeutical approaches capable of selectively killing cancer cells could represent a step forward to fight cancer.
E. Gambini, E. Reisoli, I. Appolloni, L. Menotti, Paolo Malatesta   +4 more
doaj   +1 more source

Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology Committees

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Rates of cancer among adolescents and young adults (AYA), age 15–39 years, are increasing. Consequently, radiation oncologists are treating more AYAs who have diagnoses spanning both pediatric and adult practices. Compared to pediatric and older adult patients, AYAs face a unique set of challenges.
Hesham Elhalawani, Rachel K. Peterson, Avani D. Rao, Laurie J. McKenzie, Ahmed Magdy Elmotayam, Leslie Chang, Michael Roth, Susan L. McGovern   +7 more
wiley   +1 more source

Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer

Frontiers in Oncology, 2022
Triple negative breast cancer (TNBC) refers to the subtype of breast cancer which is negative for ER, PR, and HER-2 receptors. Tumor-associated macrophages (TAMs) refer to the leukocyte infiltrating tumor, derived from circulating blood mononuclear cells
Xia Qiu, Tianjiao Zhao, Tianjiao Zhao, Ran Luo, Ran Qiu, Zhaoming Li   +5 more
doaj   +1 more source